RBQM for Emerging Biopharma: Owning What Matters Most
For emerging biopharmaceutical companies, risk-based quality management (RBQM) is more than a regulatory requirement. It is an opportunity to strengthen clinical trial oversight, protect timelines and make more informed development decisions.
As clinical trials grow in complexity, sponsors must maintain ownership of critical quality and risk decisions, even when execution is outsourced to contract research organizations (CROs). With ICH E6(R3) and E8(R1) reinforcing expectations for risk-proportionate approaches, effective sponsor oversight requires more than documented processes. It demands clear accountability, evidence-based decisions and meaningful action.
In this white paper, Syneos Health® experts explore five practical shifts that can help emerging biopharma strengthen RBQM without adding unnecessary operational complexity.
You will learn how to:
- Own critical quality decisions early by integrating critical-to-quality (CTQ) factors and quality by design (QbD) into protocol development
- Strengthen sponsor-CRO collaboration by clarifying accountability, decision-making responsibilities and oversight expectations
- Build a defensible story of control by connecting risk assessments, monitoring signals and documented actions throughout the trial lifecycle
- Develop RBQM capabilities incrementally through targeted training, practical application and cross-functional engagement
- Turn lessons learned into lasting improvements by applying insights across studies to strengthen future trial design and execution
Download the white paper to discover how your organization can take greater ownership of critical clinical trial decisions, strengthen sponsor oversight and focus resources where they matter most.
Related Content
Looking for exclusive insight?
